secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0001104659-25-020023
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax issues 2025 financial guidance and strategic update at TD Cowen conference
--------------------------------------------------------------------------------

- Provided 2025 revenue framework and combined R&D/SG&A expense guidance for 2025 and 2026.
- Reaffirmed transition of COVID-19 vaccine commercialization to Sanofi starting 2025-2026 season.
- Highlighted clinical progress on COVID-19, CIC, and standalone flu vaccine candidates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000110465925020023/0001104659-25-020023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000110465925020023/tm258153d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-020023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer